Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 
 
Play

MS: Living with the challenge

Approximately 2.3 million people worldwide are affected by multiple sclerosis (MS). This central nervous system disorder, the degree and course of which can vary greatly, disrupts the brain‘s control over vision, movement and speech. There is no cure for MS yet, however it can be treated with disease-modifying medicines so that patients can lead a normal life.
 

Cladribine tablets: Marketing authorization application

The European Medicines Agency (EMA) has accepted for review Marketing Authorization Application (MAA) of our investigational product, Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis (MS).

PRESS KIT

Press Kit

CONTACT

Gangolf Schrimpf
Gangolf Schrimpf
Phone: +49 6151 72 9591
Fax: +49 6151 72-919591
E-Mail

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 
Merck KGaA, Darmstadt, Germany on Facebook
Merck KGaA, Darmstadt, Germany on LinkedIn
Twitter